ESLA - NASDAQ

Estrella Immunopharma, Inc.

ESLA·NASDAQ

$1.17

+0.41%

HealthcareBiotechnology

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.34M

EPS-0.3500

P/E Ratio-3.34

Earnings Date06/03/2026

No Revenue Data

ESLA has not reported any revenue values in the available annual periods.

-13.06M

Net Income

48%

3Y+1211.0%

5Y+1681.0%

10Y+1681.0%

-1.79M

Operating Cash Flow

-77%

3Y+71.0%

5Y+166.0%

10Y+166.0%

Estrella Immunopharma, Inc. Profit Bridge

ESLA · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (0.00)

Gross Profit0.00

Operating Expenses

Operating Expenses (13.06M)

Operating Income-13.06M

Other Income & Taxes

Interest Expense (0.00)

Other Income/Expense0.00

Pretax Income-13.06M

Income Tax (838.00)

Net Income-13.06M

Net Income

-13.06M

Profitability Analysis

Estrella Immunopharma, Inc. Income Statement

ESLA • NASDAQ

Estrella Immunopharma, Inc. Income Statement	Dec 2025	Dec 2024	Jun 2024	Dec 2022	Jun 2022	Jun 2021
REVENUE
GROSS PROFIT
OPERATING INCOME
Operating Expenses	(13.1M)	(8.8M)	(7.3M)	(1.6M)	(1.7M)	(733.7K)
Selling, General & Administrative	(2.8M)	(2.4M)	(3.2M)	(1.4M)	(296.2K)	(276.5K)
Research & Development	(10.2M)	(6.4M)	(4.1M)	(0.0)	(1.4M)	(457.2K)
Operating Income	-13.1M	-8.8M	-7.3M	-1.6M	-1.7M	-733.7K
PRE-TAX INCOME
Net Interest Income	0.0	0.0	0.0	654.1K	1.4K	0.0
Other Expenses	(0.0)	(0.0)	(0.0)	(201.3K)	(0.0)	(0.0)
Total Other Income Expenses Net	0.0	0.0	0.0	654.1K	1.4M	0.0
Income Before Tax	-13.1M	-8.8M	-7.3M	-915.5K	-1.7M	-733.7K
NET INCOME
Income Tax Expense	(838.0)	(1.7K)	(1.6K)	(80.6K)	-235.1K	(0.0)
Net Income	-13.1M	-8.8M	-7.3M	-996.1K	-1.7M	-733.7K

SEC Filings

ESLA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-K/A 10-K/A 2025 FY (Amended) FY	April 30, 2026	December 31, 2025	2025	View Filing
10-K 10-K 2025 FY FY	March 18, 2026	December 31, 2025	2025	View Filing
S-1/A S-1/A (Amended) N/A	January 22, 2026	January 22, 2026		View Filing
S-1/A S-1/A (Amended) N/A	January 16, 2026	January 16, 2026		View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 06, 2026	January 05, 2026	2026	View Filing
S-1 S-1 N/A	December 22, 2025	December 22, 2025		View Filing
8-K 8-K 2025 N/A	December 04, 2025	December 04, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 03, 2025	2025	View Filing

Showing 1 to 10 of 106 filings

Related Guides

Blog Categories

Continue your ESLA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.